216 related articles for article (PubMed ID: 19133706)
1. Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with ocular hypertension or glaucoma: analysis based on the UK general practitioner research database.
De Natale R; Lafuma A; Berdeaux G
Clin Drug Investig; 2009; 29(2):111-20. PubMed ID: 19133706
[TBL] [Abstract][Full Text] [Related]
2. Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma: analysis conducted on the United Kingdom General Practitioner Research Database.
Lafuma A; Berdeaux G
Curr Med Res Opin; 2007 Dec; 23(12):3009-16. PubMed ID: 17958945
[TBL] [Abstract][Full Text] [Related]
3. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
4. Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects.
Halpern MT; Covert DW; Robin AL
Trans Am Ophthalmol Soc; 2002; 100():109-17; discussion 117-8. PubMed ID: 12545683
[TBL] [Abstract][Full Text] [Related]
5. A cost-effectiveness analysis of fixed-combination therapies in patients with open-angle glaucoma: a European perspective.
Hommer A; Wickstrøm J; Friis MM; Steeds C; Thygesen J; Ferreras A; Gouws P; Buchholz P
Curr Med Res Opin; 2008 Apr; 24(4):1057-63. PubMed ID: 18315942
[TBL] [Abstract][Full Text] [Related]
6. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
Netland PA; Landry T; Sullivan EK; Andrew R; Silver L; Weiner A; Mallick S; Dickerson J; Bergamini MV; Robertson SM; Davis AA;
Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France.
Payet S; Denis P; Berdeaux G; Launois R
Clin Drug Investig; 2008; 28(3):183-98. PubMed ID: 18266403
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
Noecker RJ; Walt JG
Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S15-21. PubMed ID: 16389056
[TBL] [Abstract][Full Text] [Related]
9. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma.
Parmaksiz S; Yüksel N; Karabas VL; Ozkan B; Demirci G; Caglar Y
Eur J Ophthalmol; 2006; 16(1):73-80. PubMed ID: 16496249
[TBL] [Abstract][Full Text] [Related]
10. Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs.
Schwartz GF; Tan J; Kotak S
J Ocul Pharmacol Ther; 2009 Dec; 25(6):555-61. PubMed ID: 20028264
[TBL] [Abstract][Full Text] [Related]
11. Efficiency of travoprost versus fixed-combination latanoprost/timolol.
Soto J
Clin Drug Investig; 2009; 29(8):557; author reply 558. PubMed ID: 19591517
[No Abstract] [Full Text] [Related]
12. Topical prostaglandin fixed combinations in UK primary care: observational study using data from the health improvement network.
Loftus J; Christopoulou D; Blak BT; Hards M
Eur J Ophthalmol; 2012; 22(3):376-87. PubMed ID: 22034021
[TBL] [Abstract][Full Text] [Related]
13. [Cost-efficacy analysis of fixed combinations of prostaglandin/prostamide for treating glaucoma].
Martínez A; Slof J
Arch Soc Esp Oftalmol; 2008 Oct; 83(10):595-600. PubMed ID: 18855279
[TBL] [Abstract][Full Text] [Related]
14. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
[TBL] [Abstract][Full Text] [Related]
15. Refill rates and budget impact of glaucoma lipid therapy: a retrospective database analysis.
Walt JG; Wilensky JT; Fiscella R; Chiang TH; Guckian A
Clin Drug Investig; 2007; 27(12):819-25. PubMed ID: 18020539
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study.
Chiseliţă D; Antohi I; Medvichi R; Danielescu C
Oftalmologia; 2005; 49(3):39-45. PubMed ID: 16408674
[TBL] [Abstract][Full Text] [Related]
17. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs.
Eisenberg DL; Toris CB; Camras CB
Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S105-15. PubMed ID: 12204706
[TBL] [Abstract][Full Text] [Related]
18. [The more favourable cost/effectiveness ratio of latanoprost vs bimatoprost and travoprost when using normally for treatment of glaucoma].
Soto J
Arch Soc Esp Oftalmol; 2005 Jan; 80(1):9-10; author reply 10. PubMed ID: 15692888
[No Abstract] [Full Text] [Related]
19. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
Camras CB
Am J Ophthalmol; 2002 May; 133(5):732; author reply 732-3. PubMed ID: 11992888
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of switching to travoprost/timolol fixed-combination therapy from latanoprost monotherapy.
Kashiwagi K
Jpn J Ophthalmol; 2012 Jul; 56(4):339-45. PubMed ID: 22581454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
